Biogen is investing $2 billion in its U.S. manufacturing footprint — but not in Massachusetts, where the drug company is ...

Biogen Inc. has announced a $2 billion investment to expand its manufacturing capabilities at Research Triangle Park (RTP), ...

A standoff over Elevidys could have major consequences for Duchenne patients, gene therapy companies and the perception of ...

Kostas Biliouris, BMO Capital Markets biotech analyst, joins CNBC's 'Squawk on the Street' to discuss the latest details on ...

Investing in biotechnology stocks is similar to the drug development process itself. That is, investors frequently experience ...

As the controversy over the safety of Sarepta Therapeutics’ gene therapies comes to a head, the biotech is standing firm ...

A Cambridge-based company developing gene therapies for rare diseases is laying off more than a third of its workforce.

The biotech is planning to expand antisense oligonucleotide capabilities and infrastructure on campuses that already produce ...

One of North Carolina's largest biotechnology companies is expanding its operations with a $2 billion investment.

The Supreme Court on Monday pulled up the CBI for not appearing in a matter against Indiabulls Housing Finance Limited (IHFL), now known as Sammaan Capital Limited, for allegedly disbursing dubious ...

British biopharmaceutical company GlaxoSmithKline will lay off 150 employees in its Cambridge operations by the end of March ...

Rhythm Pharmaceuticals develops medicines for rare disorders that cause weight gain. The company's only approved product is ...